MCI Trials Should Test Diagnostic Criteria In Community Settings – FDA Cmte.
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pivotal studies to support a drug for treatment of mild cognitive impairment (MCI) should include a trial in a community-based setting, FDA’s Peripheral and Central Nervous Systems Drugs Advisory Committee agreed March 13.